Feb 12, 2026 7:25 am EST Kane Biotech Restarts Commercial Activities and Strengthens North American Management
Dec 18, 2025 7:25 am EST Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
Dec 17, 2025 7:25 am EST Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
Dec 10, 2025 7:25 am EST Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
Nov 4, 2025 7:25 am EST Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
Sep 16, 2025 5:05 pm EDT Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
Sep 10, 2025 5:05 pm EDT Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
Sep 4, 2025 8:00 am EDT Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
